Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-04-30 Earnings Release
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated April 30, 2019, from Eli Lilly and Company. It specifically references Item 2.02, which is "Results of Operations and Financial Condition," and includes a press release (Exhibit 99.1) announcing the company's first quarter 2019 financial results. The text states that the press release is attached and is being furnished, not filed, and it includes unaudited operating results for the quarter ended March 31, 2019. The document itself is relatively short (3,588 characters) and primarily serves as an announcement of the earnings release rather than containing the full financial statements or detailed analysis. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2019-04-30 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy solicitation for a company's annual meeting of shareholders. It discusses the election of directors, board composition, governance issues, and recommendations for shareholder voting. The presence of the SEC header, the title 'SCHEDULE 14A', and the detailed discussion of director nominees and governance matters confirm this is a proxy solicitation document. This matches the description of Proxy Solicitation & Information Statement (PSI). The document is not an annual report, earnings release, or management report, but specifically proxy materials for shareholder voting.
2019-04-22 English
FORM 4
Director's Dealing
2019-04-17 English
FORM 4
Director's Dealing
2019-04-17 English
FORM 4
Director's Dealing
2019-04-17 English
FORM 4
Director's Dealing
2019-04-17 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.